Blog
The 2021 German Federal Election: What is the Future Outlook for Healthcare in Germany?
Published September 30, 2021
Written by Caspar Kengeter and Manon Ricard…
Blog
Poland’s Medical Fund Bill to Improve Access to Oncology Drugs
Published June 2, 2021
Executive Summary The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Briefs
COVID-19 Briefing Series: European HCP Perspectives
Highlights from Trinity’s Recent Research Focused on European HCP The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. As the EU5 countries comprise some of the most important pharmaceutical markets, and with Italy, Spain and France includes countries which have been impacted significantly from COVID-19, Trinity aimed to understand the impact on HCP engagement with Market Research. Publication access form…
White Papers
Spending Wisely in Europe
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success. In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…